Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists reduce major cardiovascular events and improve cardiac structure/function through anti-inflammatory, anti-oxidative, and metabolic mechanisms, independent of glucose lowering.
If you have T2DM and heart disease or risk factors, ask your doctor about SGLT2 inhibitors or GLP-1 RAs. These drugs do more than lower blood sugar; they actively protect your heart, reduce inflammation, and lower the risk of heart failure and death, regardless of your glucose levels.
SGLT2i and GLP1-RA have shown remarkable benefits in reducing major cardiovascular events in patients with and without T2DM... These drugs offer cardioprotection in patients with established atherosclerotic cardiovascular disease, reduce the risk of admission to the hospital for heart failure, and lower cardiovascular and all-cause mortality.
Why this rating
The paper cites multiple large-scale clinical trials and meta-analyses, though it is a review paper summarizing others' work.
Source
Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
Veronika A. Myasoedova et al. · Antioxidants · 2023
DOI 10.3390/antiox13010016
More from this paper
- SGLT2 inhibitors reduce oxidative stress and inflammation in cardiac tissue by improving nitric oxide bioavailability, stimulating Nrf2/ARE signaling, and suppressing NADPH oxidase.Good
- SGLT2 inhibitors reduce the incidence of atrial fibrillation (AF) and atrial flutter (AFL) by reducing atrial dilation, intracellular sodium/calcium levels, and epicardial adipose tissue.Good
- GLP-1 receptor agonists reduce stroke risk but do not significantly prevent the onset of atrial fibrillation or atrial flutter, and may increase heart rate.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →